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Introduction
The extent to which first acute myocardial infarction (AMI) 
with or without ST-elevation is heralded by previous symp-
tomatic atherosclerotic disease, major risk factors, or symp-
toms has important implications for understanding the 
aetiology of each phenotype, as well as the provision of 
optimal services. Studies which retrospectively evaluate 
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Abstract
Aims: It is widely thought that ST-elevation myocardial infarction (STEMI) is more likely to occur without warning (i.e. 
an unanticipated event in a previously healthy person) than non-ST-elevation myocardial infarction (NSTEMI), but no 
large study has evaluated this using prospectively collected data. The aim of this study was to compare the evolution of 
atherosclerotic disease and cardiovascular risk between people going on to experience STEMI and NSTEMI.
Methods: We identified patients experiencing STEMI and NSTEMI in the national registry of myocardial infarction for 
England and Wales (Myocardial Ischaemia National Audit Project), for whom linked primary care records were available 
in the General Practice Research Database (as part of the CALIBER collaboration). We compared the prevalence and 
timing of atherosclerotic disease and major cardiovascular risk factors including smoking, hypertension, diabetes, and 
dyslipidaemia, between patients later experiencing STEMI to those experiencing NSTEMI.
Results: A total of 8174 myocardial infarction patients were included (3780 STEMI, 4394 NSTEMI). Myocardial infarction 
without heralding by previously diagnosed atherosclerotic disease occurred in 71% STEMI (95% CI 69–72%) and 50% 
NSTEMI patients (95% CI 48–51%). The proportions of myocardial infarctions with no prior atherosclerotic disease, 
major risk factors, or chest pain was 14% (95% CI 13–16%) in STEMI and 9% (95% CI 9–10%) in NSTEMI. The rate of 
heralding coronary diagnoses was particularly high in the 12 months before infarct; 4.1-times higher (95% CI 3.3–5.0) in 
STEMI and 3.6-times higher (95% CI 3.1–4.2) in NSTEMI compared to the rate in earlier years.
Conclusions: Acute myocardial infarction occurring without prior diagnosed coronary, cerebrovascular, or peripheral 
arterial disease was common, especially for STEMI. However, there was a high prevalence of risk factors or symptoms 
in patients without previously diagnosed disease. Better understanding of the antecedents in the year before myocardial 
infarction is required.
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medical history suggest that prior atherosclerotic disease is 
common in people with AMI,1–5 and patterns differ accord-
ing to ST-elevation myocardial infarction (STEMI) and 
non-ST-elevation myocardial infarction (NSTEMI). Patients 
with NSTEMI tend to have higher levels of angina,6,7 heart 
failure symptoms,8 coronary artery bypass graft (CABG) 
and percutaneous coronary intervention (PCI),6,9,10 and 
peripheral vascular disease7 compared to patients with 
STEMI (Supplementary Table 1, available online).
However many of these studies take a single, retrospec-
tive snapshot of medical history and have important limita-
tions. They may underestimate the burden of prior disease 
(i.e. falsely inflating the estimate of unheralded AMI) and 
may poorly reflect the timing of initial and subsequent man-
ifestations of disease. To our knowledge, no large-scale 
study to date has evaluated the extent and nature of STEMI 
and NSTEMI heralding using prospectively collected infor-
mation on the onset of atherosclerotic disease (in coronary, 
cerebral, and peripheral circulations) and other risk factors.
Therefore, this paper aims to compare the evolution of 
atherosclerotic disease and cardiovascular risk between 
people going on to experience STEMI and NSTEMI. Using 
prospectively collected longitudinal primary care data 
linked to detailed hospital data on acute coronary syn-
dromes, we describe the initial manifestation, distribution 
and timing of different atherosclerotic presentations before 
first STEMI and NSTEMI, and the proportion of AMIs that 
occur without any previously diagnosed atherosclerotic 
disease, cardiovascular risk factors, or chest pain.
Methods
Study design
As part of the CALIBER research programme (Cardiovascular 
disease research using Linked Bespoke studies and Electronic 
Records, www.caliberresearch.org),11 the records of patients 
presenting with STEMI and NSTEMI in the Myocardial 
Ischaemia National Audit Project (MINAP) were linked to 
longitudinal electronic health records from primary care 
from the General Practice Research Database (GPRD).
MINAP
MINAP is the national registry of patients admitted to hos-
pitals in England and Wales with acute coronary syndrome 
(ACS).12 The MINAP dataset records timing of symptom 
onset and admission, clinical features and investigations 
(including ECG results and cardiac biomarkers), past medi-
cal history, hospital treatment, and discharge diagnosis.12
GPRD
The GPRD is a primary care database containing 
anonymized patient records from general practices for 
approximately 8% of the UK population (5.2 million 
patients).13 General practitioners (GPs) play a key role in 
the UK healthcare system as they are responsible for pri-
mary health care and specialist referrals. Patients are affili-
ated to a practice, which centralizes the medical information 
from the GP (diagnoses, symptoms, prescriptions, treat-
ments, and health behaviours), specialist referrals, and hos-
pitalizations, so that GP data provide a comprehensive 
longitudinal health record. Around 40% of the general 
practices in GPRD permit linkage of individual patient 
records with other data sources.14 Data from these prac-
tices, all in England, are used in the current study.
Linkage
Linkage of MINAP with GPRD permits researchers to 
establish a longitudinal patient journey before and after 
ACS, while providing greater clinical detail on ACS events 
than is reliably available within GPRD. All linked patients 
had general practice data and were a representative 4% 
sample of AMI cases from MINAP. The pseudoanonymized 
dataset was created using a Trusted Third Party to perform 
the linkage, based on patient NHS number, date of birth, 
gender, and postcode.15
Definition of acute myocardial infarction
STEMI or NSTEMI was defined by details recorded in 
MINAP, following the joint American Heart Association/
European Society of Cardiology definition.16 In order to 
confine the analysis to first AMI, we excluded patients with 
a history of AMI noted in their MINAP record, or with evi-
dence of AMI in their GPRD record prior to the first AMI 
recorded in MINAP. We included patients fulfilling the fol-
lowing criteria: at least 18 years of age at AMI, first AMI 
occurring between 1 January 2003 and 31 December 2008; 
registered with the GPRD practice at the time of AMI, with 
at least one year of observation before AMI and at least one 
consultation during pre-AMI follow up to allow prevalent 
diagnoses to be recorded once a patient joins a practice, as 
patients can register with a practice and not attend for many 
months or years (Supplementary Figure 1).
Identifying atherosclerotic cardiovascular 
disease and risk factors in the linked data
MINAP and GPRD data were used to identify AMI, other 
atherosclerotic disease and cardiovascular risk factors 
among study patients. Any disease, risk factor, or chest pain 
recorded at any time prior to AMI was defined as ‘herald-
ing’ the AMI. Atherosclerotic disease included cardiac dis-
ease (stable angina, unstable angina, cardiac arrest, heart 
failure, coronary heart disease (CHD) not otherwise speci-
fied, receipt of PCI and CABG), ischaemic cerebrovascular 
disease, including stroke, non-stroke cerebrovascular 
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disease, and transient ischaemic attack, and peripheral arte-
rial disease (PAD), including abdominal aortic aneurysm.
Risk factors investigated were smoking (categorized as 
non, ex, current, or unknown at the time of AMI), hyperten-
sion (either diagnosed hypertension or three consecutive 
raised (>140/90 mmHg) measurements), dyslipidaemia 
(abnormal lipid measurements or management of high 
lipids), and diabetes (diagnosed diabetes or insulin pre-
scription) and were defined by codes in the primary care or 
MINAP hospital record. We also determined whether 
patients had been prescribed blood pressure-lowering, 
lipid-lowering, or antiplatelet medications in the 6 months 
before AMI. Missing data from MINAP variables and 
absence of any diagnostic codes in the GPRD were taken to 
indicate absence of the risk factor or morbidity.
Determining onset and duration of diagnosed 
atherosclerotic disease before AMI
For patients whose AMI was heralded by a diagnosis of ath-
erosclerotic disease, we took the earliest record of any ath-
erosclerotic disease before AMI in the GPRD to be the date 
of onset (data on timing of prior disease are not recorded in 
MINAP). Where this code was for a prevalent diagnosis 
(e.g. ‘history of stroke’) or the morbidity was recorded only 
in MINAP, the date of onset was recorded as missing. The 
earliest date of each subtype of atherosclerotic disease (cor-
onary, cerebrovascular, peripheral arterial) was ascertained 
using the same method. This allowed calculation of the 
duration of diagnosed disease before AMI and the rate of 
diagnosis before STEMI and NSTEMI.
Consultation or admission for chest pain in 
the linked data
In patients without diagnosed atherosclerotic disease, we 
assessed the frequency of primary care consultations for 
chest pain.
Statistical analysis
The proportions with diagnosed atherosclerotic disease and 
risk factors were calculated for STEMI and NSTEMI 
patients. Since the age and sex profiles of STEMI and 
NSTEMI patients differed, we included each atheroscle-
rotic disease/risk factor in turn in an age- and sex-adjusted 
logistic regression model to determine whether the odds of 
prior disease/risk factor differed between STEMI and 
NSTEMI patients, after accounting for age and sex differ-
ences. We used the models to assess interaction between 
age and sex. We also calculated the age- and sex-standard-
ized prevalences of each atherosclerotic disease subtype 
and risk factor for STEMI and NSTEMI patients, using the 
age and sex distribution of the study population as the 
standard.
To investigate the timing of disease prior to AMI, we 
calculated rates of new coronary, cerebrovascular, and 
peripheral arterial disease in 1-year time bands in the period 
before AMI, and rates of new coronary diagnoses and chest 
pain consultations in 1-month time bands in the period 
before AMI. We used Poisson regression to calculate rate 
ratios and 95% confidence intervals, comparing the rate of 
coronary diagnosis in the year before AMI to the rate in the 
previous 9 years, and also to test for linear trend in the rate 
of diagnosis in the years leading to AMI. All analyses were 
performed in STATA. The study details are registered 
online at clinicaltrials.gov (NCT01379131) and a time-
stamped detailed analytic protocol is available on request. 
CALIBER has received ethics approval (ref. 09/H0810/16) 
for creation of linked pseudoanonymized data encompass-
ing GPRD and MINAP.
Results
We identified 8174 first AMI patients who met the eligibil-
ity criteria. Their median age was 71 years (IQR 59–80), 
2946 (36%) were women, and 3780 (46%) had STEMI. 
The median duration of follow up before AMI was 8.7 
years (overall 77,228 person-years of follow up). Table 1 
shows the demographic and hospital admission characteris-
tics of patients by AMI type.
Acute myocardial infarction occurring with 
and without heralding
As shown in Figure 1, among patients with STEMI, 29% 
had prior atherosclerotic disease, 56% had no prior athero-
sclerotic disease diagnosis but at least one cardiovascular 
risk factor, and 0.6% experienced only chest pain, leaving 
14% (95% CI 13–16%) unheralded by these factors. In 
NSTEMI patients, 50% had previous disease, 40% had no 
previous disease but at least one cardiovascular risk factor, 
0.7% reported only chest pain, and 9% (95% CI 9–10%) 
experienced AMI unheralded by these factors. Thus 
NSTEMIs were more often heralded by prior atheroscle-
rotic disease rather than other risk factors only. STEMIs 
were more likely to be unheralded than NSTEMIs, but the 
absolute proportions of AMIs unheralded by these factors 
were low for both types.
Diagnosed atherosclerotic disease before 
first AMI
As shown in Table 2, 3326 (41%) of patients had previously 
diagnosed atherosclerotic disease. Patients with NSTEMI 
experienced more disease (STEMI 29%, NSTEMI 50%, 
age- and sex-standardized values 32% and 47%, respec-
tively, p<0.001) and this pattern was consistent across age 
groups, for men and women and for different atheroscle-
rotic disease manifestations, even after standardizing for 
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age and sex. There was no age–sex interaction. Coronary 
disease was the most common presentation before AMI, 
diagnosed in 21% of STEMI patients and 41% of NSTEMI; 
most of these patients had stable angina (16% in STEMI 
and 33% in NSTEMI). Although most patients with previ-
ous disease had a coronary diagnosis, 9% of STEMIs and 
10% of NSTEMIs were heralded only by PAD and/or ath-
erosclerotic cerebrovascular disease.
As shown in Figure 2, 30% of patients were diagnosed 
with disease in only one arterial bed, 9% in two, and 2% in 
three. The extent of disease differed by AMI type (age- and 
sex-adjusted logistic regression p<0.001); overall, 15% of 
patients with NSTEMI had disease at more than one site, 
compared to 6% in STEMI.
Of the 3326 patients with atherosclerotic disease diag-
noses, we were able to estimate a date of disease onset for 
2891 (87%; 84% STEMI, 89% NSTEMI). Throughout the 
10 years preceding infarction, the rates of diagnosis of cor-
onary, cerebrovascular, and peripheral disease were higher 
in NSTEMI than STEMI (Figure 3). The rates of cerebro-
vascular disease and PAD remained stable throughout fol-
low up, with an upward trend towards AMI over time 
(average increase in rate per 1-year time band: 1.06, 95% 
CI 1.03–1.10; p<0.001). Rates of coronary disease were 
higher than rates of peripheral or cerebrovascular disease 
throughout follow up, consistent with the higher prevalence 
of coronary disease at the time of AMI.
In contrast to the patterns observed in cerebrovascular 
and peripheral diseases, the rate of coronary disease 
Table 1. Demographics and hospital admission characteristics of STEMI and NSTEMI patients at the time of hospital admission.
Characteristic STEMI (n=3780) NSTEMI (n=4394)
Age (years) 67.0 (57.0–77.0) 74.0 (63.0–82.0)
Female 1172 (31.0) 1774 (40.4)
Ethnicity  
 White 3146 (83.2) 3739 (85.1)
 South Asian 13 (0.3) 18 (0.4)
 Other 59 (1.6) 63 (1.4)
 Unknown 562 (14.9) 574 (13.1)
ECG at admission  
 ST-segment elevation 3552 (94.0) 0 (0)
 Left bundle branch block 87 (2.3) 246 (5.6)
 ST-segment depression 0 (0.0) 1144 (26)
 T-wave changes only 0 (0.0) 1024 (23.3)
 Other abnormality 0 (0.0) 836 (19)
 Normal ECG 0 (0.0) 473 (10.8)
 Unknown 141 (3.7) 671 (15.3)
Peak troponin at admission (µg/l)a 5.2 (1.2–25.0) 1.0 (0.3–3.9)
Heart rate at admission (bpm)a 76.0 (63.0–90.0) 80.0 (68.0–98.0)
Systolic BP at admission (mmHg)a 138.0 (120.0–157.0) 140.0 (121.0–160.0)
Values are median (interquartile range) or n (%). As shown in Table 3, previous treatment with cardiovascular medication was different in STEMI and 
NSTEMI.
aCompleteness in peak troponin, heart rate, and systolic BP was 85, 77, and 77%, respectively.
BP, blood pressure.
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Figure 1. Previous atherosclerotic disease and risk factors in 
patients with first ST-elevation myocardial infarction (STEMI, 
n=3780) and non-ST-elevation myocardial infarction (NSTEMI, 
n=4394).
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diagnosis rose rapidly in the year before AMI (Figures 3 and 
4). Compared to the rate in the previous 9 years, the rate of 
coronary diagnosis was 4.1-times higher (95% CI 3.3–5.0) 
in the year before STEMI and 3.6-times higher (3.1–4.2) in 
the year before NSTEMI. Figure 4A shows that these 
increases were largely restricted to the 3 months before 
Table 2. Prevalence (unstandardized and age- and sex-standardized) and duration of diagnosed atherosclerotic disease in patients 
with first STEMI and NSTEMI, recorded over a median 8.7 years follow up before myocardial infarction, including patients with 
atherosclerotic disease at more than one site.
STEMI (N=3780) NSTEMI (N=4394) p-value
 n (%) Standardized 
prevalence (95% CI)
Median disease 
duration (IQR)
n (%) Standardized 
prevalence (95% CI)
Median disease 
duration (IQR)
 
Any 
atherosclerotic 
disease
1112 (29.4) 32.0 (30.5–33.5) 6.2 (2.2–11.7) 2214 (50.4) 47.2 (45.8–48.5) 7.6 (3.2–13.4) <0.001
Coronary disease 788 (20.8) 22.7 (21.3–24) 4.5 (1–8.9) 1795 (40.9) 38.2 (36.8–39.5) 4.2 (1.1–9.3) <0.001
Stable angina 587 (15.5) 16.9 (15.7–18.2) 6.3 (1.4–11.4) 1442 (32.8) 30.8 (29.5–32.1) 7.2 (2.5–13.2) <0.001
Unstable angina 46 (1.2) 1.4 (1.0–1.9) 4.6 (1.8–7.9) 172 (3.9) 3.8 (3.2–4.3) 2.7 (0.3–6.9) <0.001
PCI or CABG 99 (2.6) 2.6 (2.1–3.1) 6.5 (1.5–10.7) 281 (6.4) 6.4 (5.7–7.2) 7.4 (2.0–13.1) <0.001
CHD not 
otherwise specified
404 (10.7) 11.7 (10.6–12.7) 7.3 (2.8–12.2) 969 (22.1) 20.5 (19.4–21.7) 8.1 (3.5–13.7) <0.001
Heart failure 142 (3.8) 4.6 (3.9–5.4) 4.5 (1.5–9.5) 498 (11.3) 9.9 (9.1–10.7) 4.1 (1.2–7.9) <0.001
Cardiac arrest 3 (0.1) 0.1 (0–0.1) 0.1 (0–8.3) 7 (0.2) 0.2 (0–0.3) 2.3 (0.4–18.8) 0.277
Other 
atherosclerotic 
disease
537 (13.9) 15.6 (14.4–16.8) 4.8 (1.8–9.3) 1036 (23.6) 21.7 (20.5–22.8) 5.6 (2.6–9.7) <0.001
Cerebrovascular 
disease
276 (7.3) 9.5 (8.5–10.5) 5.3 (2.2–11.3) 554 (12.6) 12.6 (11.7–13.5) 6.1 (2.8–10.9) <0.001
Peripheral arterial 
disease
261 (6.9) 7.7 (6.8–8.6) 4.4 (1.7–8.4) 565 (12.9) 12.0 (11.1–13.0) 6.1 (2.9–10.5) <0.001
Unknown initial 
presentationa
6 (0.2) 0.2 (0–0.3) 15.8 (12.7–17.6) 23 (0.5) 0.5 (0.3–0.8) 4.4 (2.1–8.1) 0.009
p-values for the association between MI subtype and each presentation (adjusted for age and sex).
CABG, coronary artery bypass graft; CHD, coronary heart disease; PCI, percutaneous coronary intervention.
aWhere the only code indicating atherosclerotic disease was unspecific.
Figure 2. Proportions of patients with ST-elevation myocardial infarction (STEMI, n=3780) and non-ST-elevation myocardial 
infarction (NSTEMI, n=4394) with different combinations of disease in one, two, or three arterial beds; 71% of STEMI patients 
and 50% of NSTEMI patients were unheralded by atherosclerotic disease at any site. CHD, coronary heart disease; CVD, 
cerebrovascular disease; PAD, peripheral arterial disease.
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infarct, during which 159 (2%) patients were first diagnosed 
with coronary disease or received a coronary intervention 
(102 stable angina, 17 unstable angina, 26 CHD of unspeci-
fied type, 14 PCI/CABG). A similar pattern was observed in 
the rate of chest pain consultations in patients without diag-
nosed atherosclerotic disease (Figure 4B).
Among patients with prior atherosclerotic disease, the 
median duration between first diagnosis and STEMI 
was 6.2 years (IQR 2.2–11.7) and in NSTEMI 7.6 years 
(3.2–13.4) (Table 2). The median duration of all atheroscle-
rotic diseases combined was longer in NSTEMI at all age 
groups and for men and women (Supplementary Table 2). 
Importantly, the duration of diagnosed disease tended to be 
long: 26% of atherosclerotic disease heralding in STEMI 
and 35% in NSTEMI was 10 or more years’ duration (48% 
and 57% 5 or more years, respectively).
Use of cardiovascular medications in 
patients with atherosclerotic disease
Of those with previously diagnosed atherosclerotic disease, 
87% were being prescribed one or more of aspirin, statins, 
and blood-pressure-lowering treatment in the 6 months 
before AMI, but only 34% were receiving all three.
Cardiovascular risk factors and medications in 
patients without previous atherosclerotic disease
Fifty-nine per cent of AMIs were unheralded by previ-
ously diagnosed atherosclerotic disease (71% STEMI, 
95% CI 69–72%; 50% NSTEMI, 95% CI 48–51%). 
Overall, 79% of these patients had at least one elevated or 
treated risk factor (ever had a record of diabetes, hyper-
tension, dyslipidaemia, current smoking, or a prescrip-
tion for statins, blood pressure-lowering, or antiplatelets 
in the 6 months before AMI). This was the same in 
STEMI (79%) and NSTEMI (80%) (Table 3). The most 
common risk factors were diagnosed hypertension or 
recent use of blood pressure-lowering drugs (42% of 
STEMI patients and 53% of NSTEMI) and current smok-
ing (39.8% STEMI, 28.3% NSTEMI); one or both of 
these risk factors was present in 70% of STEMI and 80% 
of NSTEMI patients. STEMI patients tended to have a 
slightly lower burden of cardiovascular risk factors than 
NSTEMI (median two risk factors in STEMI patients, 
three in NSTEMI).
Patients without heralding by previous 
atherosclerotic disease, risk factors, medications, 
or chest pain
In STEMI patients, 546 (14%) were unheralded by all of 
the factors discussed and in NSTEMI patients, 413 (9%). 
These patients were more likely to be younger and men 
than those who were heralded (heralded median age 71 
years (IQR 60–80), 63% men; unheralded median age 67 
years (IQR 58–77), 72% men). They were also likely to 
have a lower rate of consultation with the GP in the period 
leading to AMI (median 7 consultations per year in patients 
heralded by anything, compared to 4 per year in those 
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Figure 3. Rates of coronary heart disease (CHD), peripheral arterial disease (PAD) and cerebrovascular disease (CVD) in the 10 
years before diagnosis of ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), with 
95% confidence intervals. Each time point covers a 1-year time band (1=0–1 years before AMI, 2=1–2 years before AMI, etc).
Herrett et al. 241
unheralded). The proportions of patients by age group are 
shown in Supplementary Figure 2.
We conducted a sensitivity analysis including family 
history of cardiovascular disease and obesity as cardiovas-
cular risk factors. This reduced the proportion of STEMIs 
unheralded by disease, risk factors, or chest pain from 14% 
to 9% and NSTEMIs from 9% to 7%.
Discussion
We found that heart attack without previous clinically 
ascertained and recorded atherosclerotic disease was com-
mon, but due to the high prevalence of elevated cardiovas-
cular disease risk factors, it was rare for heart attack to 
occur without warning by disease, risk factors, or chest 
0.0
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Figure 4. Rates of coronary diagnosis (A) and chest pain consultations (B) in the months leading to ST-elevation myocardial 
infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI), with 95% confidence intervals. Consultations for chest 
pain are only in those without diagnosed atherosclerotic disease. Each time point covers a 1-month time band (0–1 months, 1–2 
months, etc). NB: Figure 4B describes chest pain consultations in only patients without previously diagnosed atherosclerotic disease, 
therefore describing that although these patients have not received a coronary disease diagnosis, they may well be heralded by 
possible coronary symptoms.
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pain. In the first large-scale evaluation of coronary, cere-
bral, and peripheral atherosclerotic disease manifesta-
tions, risk factors, and symptoms prior to STEMI and 
NSTEMI using prospectively collected data, we found 
large differences in the pattern of diagnosed atheroscle-
rotic disease by AMI type in the period leading up to AMI. 
While the proportion of AMI that occurs without disease, 
cardiovascular risk factors, medications, or chest pain (i.e. 
‘out of the blue’) was slightly higher in STEMI, an impor-
tant proportion of unheralded AMIs are NSTEMI (14% 
vs. 9%, respectively). We also found that there was a pre-
monitory period for both AMI types during which the 
rates of both coronary disease diagnosis and chest pain 
consultation were raised, but there was no equivalent 
increase in the rate of peripheral artery or cerebrovascular 
disease diagnoses.
Previous atherosclerotic disease and risk factors
Uniquely, our study provided prospective data on the rate 
of onset of different subtypes of atherosclerotic disease in 
the years leading to AMI. Patients with NSTEMI had a con-
sistently higher rate of coronary, cerebrovascular and 
peripheral disease diagnosis throughout follow up com-
pared to STEMI. This is in line with other studies showing 
that patients with NSTEMI are more likely to have prior 
atherosclerotic disease than STEMI patients (Supplementary 
Table 1).6–10,17,18
Our results describing the extent of disease across vas-
cular territories are also similar to published findings for 
NSTEMI,5 and we have shown that in STEMI patients, dis-
ease in two or more sites is less common. This is consistent 
with the idea that NSTEMI patients tend to be a sicker 
group overall. The widely different pattern in the preva-
lence and rate of onset of atherosclerotic disease between 
AMI types lends support to the hypothesis that STEMI and 
NSTEMI are two different pathophysiological entities 
(NSTEMI is more often caused by a non-occlusive throm-
bus and STEMI is more often caused by a complete 
occlusion19).
If AMI occurs without prior symptomatic atheroscle-
rotic disease, to what extent can it be considered to occur 
‘out of the blue’? Although a substantial proportion of 
infarcts were unheralded by diagnosed atherosclerotic dis-
ease, the majority of these had at least one cardiovascular 
risk factor (smoking, hypertension, dyslipidaemia, diabe-
tes) or were being treated with a cardiovascular medication. 
Our sensitivity analysis indicated that inclusion of a family 
history of cardiovascular disease and obesity as risk factors 
increased this majority. The relatively high prescription of 
antiplatelets before both STEMI and NSTEMI indicates 
that GPs suspected a high risk of atherosclerotic disease in 
Table 3. Prospectively collected evaluation of prevalence (standardized and unstandardized) of cardiovascular risk factors and 
cardiovascular medications in STEMI (n=2268) and NSTEMI (n=2180) patients without previously diagnosed atherosclerotic disease.
STEMI (n=2668) NSTEMI (n=2180) p-value
 n (%) Age- and sex-standardized 
prevalence (95% CI)
n (%) Age- and sex-standardized 
prevalence (95% CI)
 
Smoking  
 Non 339 (12.7) 13.4 (12.1–14.6) 338 (15.5) 15.0 (13.5–16.5) <0.001
 Former 1261 (47.3) 48.8 (47–50.5) 1219 (55.9) 54.0 (52–56)  
 Current 1063 (39.8) 37.4 (35.7–39) 616 (28.3) 30.5 (28.6–32.3)  
 Unknown 5 (0.2) 0.2 (0–0.4) 7 (0.3) 0.3 (0.1–0.5)  
Hypertension 1083 (40.6) 41.9 (40.1–43.7) 1082 (49.6) 47.7 (45.7–49.7) <0.001
Dyslipidaemia 569 (21.3) 21.4 (19.9–22.9) 459 (21.1) 21.4 (19.7–23.1) 0.913
Diabetes 276 (10.3) 10.6 (9.4–11.7) 302 (13.9) 13.4 (12–14.7) 0.002
Blood pressure-loweringa 806 (30.2) 31.8 (30.1–33.5) 880 (40.4) 38.3 (36.4–40.2) <0.001
Statinsa 430 (16.1) 16.3 (14.9–17.6) 404 (18.5) 18.4 (16.8–20) 0.043
Antiplateletsa 420 (15.7) 16.3 (14.9–17.7) 509 (23.3) 22.9 (21.1–24.6) <0.001
Chest pain consultationb in 90 days 
before MI
122 (4.6) 4.7 (3.9–5.4) 158 (7.2) 7.4 (6.3–8.5) <0.001
Without any of these risk factors 
or cardiovascular medications  
(% of unheralded MI)a
567 (21.3) 21.4 (19.8–22.9) 443 (20.3) 20.3 (18.6–22) 0.318
Without any of these risk factors 
or cardiovascular medications  
(% of all MI)a
567 (15) 14.7 (13.6–15.8) 443 (10.1) 10.8 (9.8–11.7) <0.001
p-values for the association of risk factor with MI subtype (adjusted for age and sex).
aPrescribed in the 6 months before MI.
bExcluding consultations recorded for administrative and prescription purposes only.
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many of these patients. Our findings are consistent with 
other prospective studies showing high risk factor burdens 
in AMI patients overall (Supplementary Table 3).20,21 To 
our knowledge, there are no other estimates for the propor-
tion of STEMI and NSTEMI occurring without heralding. 
We have shown that unheralded AMI is uncommon, occur-
ring in roughly one in 10 patients in our study, and more 
often in younger men. The true prevalence of unheralded 
AMI is likely to be lower than our data suggest because our 
data were from general practice where risk factors are 
recorded opportunistically during patient consultations.
Premonitory period
Clinical experience and retrospective studies have long 
suggested that AMI might be preceded by premonitory 
symptoms of chest pain presenting to a family physician or 
ambulatory care.22,23 Our study extends knowledge in sev-
eral respects. First, we confirmed this association with pro-
spective data. Second, we found that there were increases 
in coronary disease diagnoses and chest pain consultations 
in both STEMI and NSTEMI. This is in contrast to the 
widely held view that STEMI is usually of sudden onset. 
Third, we showed that the increases were specific to coro-
nary diagnoses and chest pain, rather than disease in cere-
bral or peripheral circulations, suggesting a local rather 
than systemic pro-thrombotic state.
Clinical implications and missed 
opportunities for care?
In patients with previously diagnosed atherosclerotic dis-
ease or risk factors, AMI represents the unmet potential of 
secondary or primary prevention, respectively. Despite a 
clear premonitory period where many patients were diag-
nosed with coronary disease shortly before AMI, the major-
ity of disease was diagnosed long in advance of both AMI 
types. Therefore, there is an extended period during which 
secondary prevention could be implemented. Our data 
describing the use of secondary prevention measures in the 
6 months before AMI showed that most patients with diag-
nosed atherosclerotic disease were receiving one of either 
statins, aspirin, or blood pressure-lowering drugs, but only 
a third were in receipt of all three, indicating that there are 
likely to be missed opportunities for secondary prevention 
in this group.
Interestingly, while coronary disease was the most com-
mon pre-AMI presentation, 10% of both STEMIs and 
NSTEMIs were heralded by peripheral artery disease and/
or cerebrovascular disease alone. This emphasizes the 
importance of further efforts to improve secondary preven-
tion following diagnoses in the cerebral and peripheral 
arteries in order to prevent an important proportion of AMI. 
The high prevalence of risk factors in both STEMI and 
NSTEMI suggests the importance of tackling the widely 
reported missed opportunities for implementation of exist-
ing interventions known to be effective.24–27 Additionally, 
the categorization of continuous measures in this analysis 
may have been an over-simplification of cardiovascular 
risk. Although a binary indicator is simple to interpret in 
studies and a useful basis on which to prescribe treatment, 
it does not reflect the continuum of risk over the full range 
of measurements. A more detailed investigation of these 
risk factors might reveal borderline raised risk in many 
patients and lowering blood pressure and lipids in those not 
diagnosed as hypertensive or dyslipidaemic may also pre-
vent AMI. However, the implications of our analysis are 
limited by a lack of comparison to AMI-free controls. Such 
a comparison may allow further conclusions to be drawn 
from these data.
Strengths
The main strength of this study is the quality of data from 
the linked MINAP and GPRD records. MINAP collects 
data from all hospitals in England and undergoes annual 
assessments to ensure the data are of research quality.28 
ECG and cardiac marker results are recorded and our 
STEMI and NSTEMI case definitions were based on the 
international definition of AMI.16 The recording of admis-
sion date in MINAP allowed us to interpret the timing of 
previous atherosclerotic disease diagnoses in relation to 
AMI. The GPRD is representative of the UK population13 
and roughly half of GPRD practices consented to linkage 
with MINAP; patients in practices that participated in the 
linkage were representative of the GPRD as a whole.14
The primary care GPRD data are collected prospectively 
as part of usual clinical care and therefore are not subject to 
recall bias or differential error related to outcome. Data 
regarding new diagnoses and treatment of disease were 
available for a median of 8.7 years before AMI, allowing 
sufficient time for incident diagnoses to arise and be 
recorded. The GPRD closely monitors data quality and the 
recording of a wide range of atherosclerotic disease out-
comes have undergone validation in GPRD studies, which, 
for example, have compared the electronic data to paper-
based medical records or compared the rate of a condition 
in the GPRD to an external source. These have shown most 
diagnoses to be of high quality.29–32
For the recording of cardiovascular disease, concord-
ance between GPRD and MINAP was over 90%, and for 
risk factors and medications was over 80% (assuming 
missingness in MINAP was concordant with a complete 
GPRD record); these values represent further evidence of 
data quality.
Our analysis was based on patients with ‘definite’ ath-
erosclerotic disease diagnoses, using diagnostic codes 
which had been rated by two clinicians as being indicative 
of disease. If ‘possible’ diagnoses were included, the pro-
portion with previous disease rose from 41% to 44%; this 
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small change indicates that our ‘definite’ atherosclerotic 
disease definition had high sensitivity.
Weaknesses
This study included only patients hospitalized with their 
first AMI recorded in MINAP data and therefore our results 
cannot be generalized to patients who die outside hospital 
or those with recurrent AMI, in whom the prevalence of 
heralding factors is likely to differ. Data were not available 
in this study to describe the numbers of patients who had 
out of hospital fatal AMI, but data from a further CALIBER 
study33 suggest that MINAP captures 30% of patients with 
AMI recorded as their cause of death.
Because our analyses of heralding are based largely on 
general practice data, symptomatic atherosclerotic disease 
may be undiagnosed if patients do not consult their GP. 
We excluded only fourteen patients without any consulta-
tions as these patients never had an opportunity for meas-
urement of risk factors or morbidity. However, introducing 
a minimum consultation rate could introduce a bias 
towards sicker patients. The data available for this analy-
sis did not allow us to differentiate between patients with 
a low consultation rate because of good health and those 
that did not consult despite symptomatic disease. 
Excluding patients with less than one year of follow up 
prior to AMI may also have introduced a selection bias if 
patients who tend to move practices more frequently are 
different to patients who stay in a practice for longer peri-
ods. However, shortening this time period would likely 
lead to misclassification of disease and an absence of car-
diovascular risk factor records as the GP would not have 
sufficient time to record these.
Implications for research
A small but important proportion of STEMI and NSTEMI 
do appear to occur with no recognized heralding signs and 
further research is warranted to better characterize these 
phenotypes, their causes and their prognosis. For patients 
with different forms of heralding the challenge remains to 
better characterize short term risk of coronary events in 
order to identify for which patients this represents a (poten-
tially remediable) premonitory period.
A research priority would be an analysis comparing 
AMI patients to a control group without AMI, including a 
comparison of missed opportunities for care in measuring 
and controlling elevated risk.
Patients with NSTEMI were more likely to have been in 
receipt of cardiovascular medications but the causal rela-
tionship between medications and severity of AMI is 
unclear. CALIBER data present a new opportunity to study 
the effects of medications in a population for whom detailed 
information regarding risk factors and prescription of medi-
cations are collected.
Conclusion
The majority of STEMIs and NSTEMI were heralded by 
prior disease or at least one other risk factor, suggesting that 
opportunities for prevention may be being missed.
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